Skip to content

Safety and efficacy evaluation of transarterial fluorescence staining-guided laparoscopic anatomic resection based on portal territory: A Multicenter Retrospective Cohort Study

Safety and efficacy evaluation of transarterial fluorescence staining-guided laparoscopic anatomic resection based on portal territory: A Multicenter Retrospective Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107153
Enrollment
Unknown
Registered
2025-08-05
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hepatic Carcinoma

Interventions

Arterial Staining Group:None
The conventional resection group:None

Sponsors

Beijing Tsinghua Changgung Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 80 years, any gender; 2. Good physical condition, without severe underlying diseases of the heart, lungs, kidneys, etc.; 3. No contraindications for Digital Subtraction Angiography (DSA), and able to tolerate laparoscopic hepatectomy; 4. Good liver function, Child-Pugh classification Grade A; 5. Preoperative indocyanine green 15-minute retention rate (ICG-R15) = 40%; 6. Barcelona Clinic Liver Cancer (BCLC) stage 0-A, with tumor diameter <= 5 cm; 7. No major vascular invasion, thrombosis, or tumor thrombus formation; 8. No distant metastasis.

Exclusion criteria

Exclusion criteria: 1. Primary liver cancer with extrahepatic metastasis; 2. Diffuse hepatocellular carcinoma; 3. Patients with a history of chemotherapy, radiotherapy, targeted therapy, or immunotherapy; 4. Recurrent hepatocellular carcinoma; 5. Patients with ruptured tumor and bleeding; 6. Patients with tumors located adjacent to major central vessels; 7. Patients with severe cirrhosis or insufficient future liver remnant volume; 8. Patients converted to open surgery during the operation; 9. Patients allergic to indocyanine green (ICG); 10. Patients unwilling or unable to cooperate with follow-up; 11. Other reasons deemed by the researcher that the patient should not be included.

Design outcomes

Primary

MeasureTime frame
Overall survival rate and disease-free survival rate in the first and second year after surgery.;

Secondary

MeasureTime frame
Surgical Time;Blood loss;Hepatic pedicle clamping time;Postoperative blood test indicators;Incidence of complications within 30 days postoperatively;Postoperative mortality related to the surgery;

Countries

China

Contacts

Public ContactYan Jun

Beijing Tsinghua Changgung Hospital

15688615630@163.com+86 156 8861 5630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026